← Back to Search

Sleep Schedule Restriction for Alzheimer's Disease (ALPS Trial)

N/A
Recruiting
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 65-85
Be older than 65 years old
Must not have
Current use of sedating drugs used at bedtime
Severe obesity (BMI > 40)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights
No Placebo-Only Group

Summary

This trial will explore whether better sleep can help mitigate the effects of Alzheimer's disease.

Who is the study for?
This trial is for older adults aged 65-85 with sleep difficulties but without severe psychiatric conditions, heavy alcohol or caffeine consumption, CNS diseases like Alzheimer's, or certain medications that affect sleep. Participants should have normal vision and hearing (with aids if necessary), a tendency to wake up often at night, and not be involved in shift work.
What is being tested?
The study tests whether restricting the time spent in bed can improve deep sleep and cognitive function in older adults. It aims to see if this intervention can reduce brain overactivity related to Alzheimer's disease risk by enhancing slow-wave activity during sleep.
What are the potential side effects?
Since the intervention involves behavioral changes rather than medication, side effects may include increased tiredness due to restricted time in bed but are otherwise minimal compared to drug treatments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 65 and 85 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I take medication to help me sleep at night.
Select...
My BMI is over 40, indicating severe obesity.
Select...
I have a long-term health issue that greatly impacts my sleep.
Select...
I had a car accident or a close call because of falling asleep in the last year.
Select...
I have a history of serious brain or nervous system conditions.
Select...
I am currently taking medication that affects my sleep.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Amyloid positivity status
Change in mean Plasma amyloid-beta 1-42
Mean change in Hippocampal Activation
+3 more
Secondary study objectives
Apolipoprotein (ApoE) e4 allele carrier status
Clinical insomnia status
Cognitive status based on neuropsychological adjudication
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Time in Bed RestrictionExperimental Treatment2 Interventions
Time in Bed (TIB) restriction of 85% of habitual TIB.
Group II: ControlActive Control1 Intervention
Participants will follow their typical sleep schedule consistent with measured average sleep and wake times.

Find a Location

Who is running the clinical trial?

University of PittsburghLead Sponsor
1,792 Previous Clinical Trials
16,359,870 Total Patients Enrolled
16 Trials studying Sleep
2,570 Patients Enrolled for Sleep
National Institute on Aging (NIA)NIH
1,802 Previous Clinical Trials
28,193,865 Total Patients Enrolled
10 Trials studying Sleep
956 Patients Enrolled for Sleep

Media Library

Time in Bed Restriction Clinical Trial Eligibility Overview. Trial Name: NCT05138848 — N/A
Sleep Research Study Groups: Control, Time in Bed Restriction
Sleep Clinical Trial 2023: Time in Bed Restriction Highlights & Side Effects. Trial Name: NCT05138848 — N/A
Time in Bed Restriction 2023 Treatment Timeline for Medical Study. Trial Name: NCT05138848 — N/A
Sleep Patient Testimony for trial: Trial Name: NCT05138848 — N/A
~38 spots leftby May 2026